Retatrutide (15mg)

Research Overview

The first triple-incretin receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 data demonstrated the largest weight reductions reported for any anti-obesity molecule, positioning it as a next-generation metabolic research compound.

Origin: Triple GIP/GLP-1/glucagon receptor agonist by Eli Lilly

Mechanism of Action

• GIP receptor agonism

• GLP-1 receptor agonism

• Glucagon receptor agonism (energy expenditure)

• Hepatic lipid metabolism enhancement

• Appetite suppression via CNS pathways

Primary Research Areas

• Obesity

• NASH

• Metabolic syndrome

• Triple-incretin signaling

• Energy expenditure

Key Published Findings

• Phase 2: up to 24.2% body weight reduction at 48 weeks (highest reported for any molecule)

• Glucagon component uniquely increases energy expenditure

• Significant reduction in liver fat content in NAFLD models

Research Protocol

Commonly studied routes: Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.

Storage

2-8°C

Important Notice

Retatrutide (15mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.